2,48 $
0,60 %heute
Nasdaq, 1. März, 21:47 Uhr
ISIN
US5288723027
Symbol
LXRX
Berichte
Sektor
Industrie

Lexicon Pharmaceuticals, Inc. Aktie News

Positiv
Seeking Alpha
etwa ein Monat alt
Lexicon Pharmaceuticals has made progress in getting its lead drug Inpefa onto formularies and securing reimbursement agreements with insurers. Multiple studies support the cost efficacy of Inpefa for heart failure, and this could become a more significant competitive differentiator for insurers if real-world experience follows accordingly. Lexicon also has other opportunities in its pipeline, ...
Positiv
The Motley Fool
etwa ein Monat alt
Wall Street enjoyed a phenomenal 2023, with growth stocks leading the broader market higher. Consensus estimates suggest three fast-paced stocks will see their sales skyrocket by 112% to 1,106% in 2024.
Positiv
Seeking Alpha
etwa 2 Monate alt
LXRX is ~60% of its May highs, despite holding an FDA-approved key drug, Inpefa, in its portfolio. The sell-off can be largely attributed to concerns over Inpefa's market uptake amid a perfect storm of competition from pharma heavyweights like Eli Lilly. I explain why I think these concerns may be overrated.
Positiv
The Motley Fool
etwa 2 Monate alt
Wall Street produced stellar gains in 2023, with the growth-focused Nasdaq Composite rallying 43%. This year is shaping up to be a stock picker's market.
Positiv
The Motley Fool
2 Monate alt
Growth stocks were responsible for powering the major stock indexes higher in 2023. The prospect of interest rate cuts by the nation's central bank has Wall Street collectively bullish on growth stocks.
Neutral
GlobeNewsWire
2 Monate alt
THE WOODLANDS, Texas, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the 42nd Annual JPMorgan Healthcare Conference taking place January 8 – January 12, 2024.
Neutral
GlobeNewsWire
3 Monate alt
The PROGRESS study marks initiation of the late-stage development program for AAK1 inhibitor LX9211, with potential to become the first new, non-opioid drug therapy in high-unmet need neuropathic pain in more than 20 years
Neutral
GlobeNewsWire
3 Monate alt
THE WOODLANDS, Texas, Nov. 22, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the following investor conferences taking place November 29 - December 1, 2023:
Mehr News anzeigen

Kostenlos registrieren

aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.

Die Apple Aktie im Überblick mit Charts, aktuellen Kennzahlen, Nachrichten und Aktienanalysen.
Die besten Dividenden-Aktien in der Dividenden-Topscorer-Liste.
Aktienanalysen der besten Aktien weltweit.
Jetzt Vermögen aufbauen